scholarly journals Angioimmunoblastic T-cell Lymphoma: A Case Report

2021 ◽  
Keyword(s):  
T Cell ◽  
Cell Lymphoma ◽  
Treatment Options ◽  
Treatment Strategies ◽  
T Cell Lymphoma ◽  
Angioimmunoblastic T Cell Lymphoma ◽  
Night Sweats ◽  
Multi Agent ◽  
Multiple Cycles ◽  
Diagnostic Modalities

Angioimmunoblastic T-cell lymphoma (AITL) is a rare, aggressive type of non-Hodgkin's lymphoma (NHL) that is mostly diagnosed in elderly patients. Its non-specific clinical presentation (lymphadenopathy, fever, night sweats, weight loss, generalized rash, and hepatosplenomegaly) often results in a delay in the diagnosis. The diagnosis is mainly established based on a detailed clinical evaluation and biopsy findings, and currently, available treatment options include corticosteroids, immunotherapy, and single- or multi-agent chemotherapy. Here, we report a case of a 61-year-old male who presented with complaints of easy fatigability, dyspnea, and fever along with inguinal lymphadenopathy and was diagnosed as a case of AITL. He was given multiple cycles of R-CHOP chemotherapy (Cytoxan, Hydroxyrubicin, Oncovin, Prednisone chemotherapy regimen), which led to tumor eradication. The patient, however, expired due to unknown reasons. The case highlights the major diagnostic modalities and treatment strategies for AITL and sheds light on the poor prognosis of the disease despite adequate management.

scholarly journals Strategies for Relapsed Peripheral T-Cell Lymphoma: The Tail That Wags the Curve

2013 ◽  
Vol 31 (16) ◽  
pp. 1922-1927 ◽  
Author(s):  
Matthew A. Lunning ◽  
Alison J. Moskowitz ◽  
Steven Horwitz
Keyword(s):  
T Cell ◽  
Cell Lymphoma ◽  
Treatment Options ◽  
Cervical Lymphadenopathy ◽  
Complete Response ◽  
Cell Receptor ◽  
Additional Treatment ◽  
T Cell Lymphoma ◽  
Hla Typing ◽  
Angioimmunoblastic T Cell Lymphoma

A 69-year-old woman was referred for further evaluation and management of relapsed angioimmunoblastic T-cell lymphoma. At diagnosis, she received six cycles of dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) and achieved a complete response (CR). Her first surveillance computed tomography scan 3 months later demonstrated enlarging cervical lymphadenopathy. A lymph node excision confirmed relapsed angioimmunoblastic T-cell lymphoma with atypical lymphocytes expressing CD3, CD4, CD10, PD-1, and EBER, with loss of CD5 ( Fig 1 ). A clonal T-cell receptor beta and gamma rearrangement by polymerase chain reaction was identical to that in her initial diagnostic biopsy. At our initial consultation, options for standard as well as investigational therapies were discussed, and HLA typing was initiated. The patient was enrolled onto an investigational phase II study; however, she developed progressive disease after two cycles. She was then treated with romidepsin 14 mg/m2 administered intravenously for 3 consecutive weeks with 1 week off. After two cycles, she achieved a partial response, and after four additional cycles, she maintained her response without further improvement. We discussed additional treatment options.

Long-term survival of the nasal NK/T cell lymphoma

2008 ◽  
Vol 149 (17) ◽  
pp. 801-805
Author(s):  
Péter Rajnics ◽  
László Krenács ◽  
András Kenéz ◽  
Zoltán Járay ◽  
Enikő Bagdi ◽  
...  
Keyword(s):  
T Cell ◽  
Treatment Guidelines ◽  
Cell Lymphoma ◽  
Treatment Options ◽  
Diagnostic Procedures ◽  
T Cell Lymphoma ◽  
Term Survival ◽  
Barr Virus ◽  
Significant Difference ◽  
Nk T Cell

The nasal NK/T cell lymphoma is a rare, extranodal non-Hodgkin lymphoma in western civilizations, which has poor prognosis. The Epstein–Barr virus can be detected in tumor cells in nearly all cases. There are no definite treatment guidelines in our days. There is no significant difference in survival between radiotherapy and chemotherapy according to Asian studies. In this case study we show our diagnostic procedures, our treatment options and we present the summary of this illness based on the data found in the literature.

Two Cases of Angioimmunoblastic T-cell Lymphoma Presenting with a Skin Eruption

2012 ◽  
Vol 74 (4) ◽  
pp. 399-404
Author(s):  
Kana KOZONO ◽  
Kazuhiko YAMAMURA ◽  
Toshihiko MASHINO ◽  
Masutaka FURUE ◽  
Hideki ASAOKU ◽  
...  
Keyword(s):  
T Cell ◽  
Skin Eruption ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Angioimmunoblastic T Cell Lymphoma

scholarly journals A novel prognostic model for angioimmunoblastic T-cell lymphoma: A retrospective study of 55 cases

2021 ◽  
Vol 49 (5) ◽  
pp. 030006052110132
Author(s):  
Jie Sun ◽  
Sha He ◽  
Hong Cen ◽  
Da Zhou ◽  
Zhe Li ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
T Cell ◽  
Prognostic Model ◽  
Proportional Hazards Model ◽  
Cell Lymphoma ◽  
Initial Diagnosis ◽  
Cox Proportional Hazards Model ◽  
T Cell Lymphoma ◽  
Chinese Patients ◽  
Angioimmunoblastic T Cell Lymphoma

Objective To explore prognostic factors and develop an accurate prognostic prediction model for angioimmunoblastic T-cell lymphoma (AITL). Methods Clinical data from Chinese patients with newly diagnosed AITL were retrospectively analysed. Overall survival (OS) and progression-free survival (PFS) were estimated using Kaplan-Meier method survival curves; prognostic factors were determined using a Cox proportional hazards model. The sensitivity and specificity of the predicted survival rates were compared using area under the curve (AUC) of receiver operating characteristic (ROC) curves. Results The estimated 5-year OS and PFS of 55 eligible patients with AITL were 22% and 3%, respectively. Multivariate analysis showed that the presence of pneumonia, and serous cavity effusions at initial diagnosis were significant prognostic factors for OS. Based on AUC ROC values, our novel prognostic model was superior to IPI and PIT based models and suggested better diagnostic accuracy. Conclusions Our prognostic model based on pneumonia, and serous cavity effusions at initial diagnosis enabled a balanced classification of AITL patients into different risk groups.

scholarly journals Angioimmunoblastic T-cell lymphoma-like lymphadenopathy in mice transgenic for human RHOA with p.Gly17Val mutation

2020 ◽  
Vol 9 (1) ◽  
pp. 1746553
Author(s):  
Gyu Jin Lee ◽  
Yukyung Jun ◽  
Hae Yong Yoo ◽  
Yoon Kyung Jeon ◽  
Daekee Lee ◽  
...  
Keyword(s):  
T Cell ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Angioimmunoblastic T Cell Lymphoma

scholarly journals Not your typical morbilliform rash: Angioimmunoblastic T‐cell lymphoma

2021 ◽  
Vol 9 (6) ◽  
Author(s):  
Wendi Bao ◽  
Kendall L. Buchanan ◽  
Loretta S. Davis
Keyword(s):  
T Cell ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Angioimmunoblastic T Cell Lymphoma ◽  
Morbilliform Rash
Sign in / Sign up

Export Citation Format

Share Document